Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis
- 12 January 2012
- journal article
- research article
- Published by Taylor & Francis in The European Journal of Contraception & Reproductive Health Care
- Vol. 17 (1) , 7-29
Abstract
Objective A systematic review of studies published between January 1995 and April 2010 aimed at determining the effect of combined hormonal contraceptives (CHCs), administered orally, transdermally or vaginally, on the risk of venous thromboembolism (VTE). Results Of the 625 potentially eligible references reviewed, 25 studies meeting the inclusion and exclusion criteria were entered in the meta-analysis. The pooled relative risks of VTE associated with the various CHCs, depending on their progestogen, were: gestodene vs. levonorgestrel 1.33 (95% confidence interval [CI]: 1.08–1.63); desogestrel vs. levonorgestrel 1.93 (95% CI: 1.31–2.83); and drospirenone vs. levonorgestrel 1.67 (95% CI: 1.10–2.55). The pooled adjusted odds ratio for norgestimate vs. levonorgestrel was 1.11 (95% CI: 0.84–1.46) and that for cyproterone acetate vs. levonorgestrel 1.65 (95% CI: 1.30–2.11). Conclusions The safest CHCs in terms of VTE are those containing levonorgestrel or norgestimate. The risk of VTE associated with desogestrel-, drospirenone- or cyproterone acetate-containing CHCs is greater than that associated with CHCs containing levonorgestrel. The increased risk of VTE found for CHCs with gestodene compared to CHCs with levonorgestrel seems smaller than in previous analyses. There were no differences in VTE risk between oral and transdermal CHCs containing norgestimate or norelgestromin, respectively.Keywords
This publication has 62 references indexed in Scilit:
- Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosisContraception, 2008
- Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutationsBritish Journal of Haematology, 2007
- Sex hormone–binding globulin—A surrogate marker for the prothrombotic effects of combined oral contraceptivesAmerican Journal of Obstetrics and Gynecology, 2004
- Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette®): observational studies using the UK General Practice Research DatabasePharmacoepidemiology and Drug Safety, 2003
- Mortality in relation to oral contraceptive use and cigarette smokingThe Lancet, 2003
- Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over studyThe Lancet, 1999
- Venous thromboembolism amng new users of different oral contraceptives.The Lancet, 1999
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control studyThe Lancet, 1995
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986